Developer docs
API playgroundTry for free, no card

Search company profiles

AcuFocus

Full company profile

uuid0002e5n

Namestring
AcuFocus
Websiteurl
acufocus.com
Company typeenum
Private
Founded yearint
2001
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
ocular implants, vision correction devices, ophthalmic medical devices, presbyopia treatment, refractive surgery implants
Industry2 codes
PRIMARYHLAHAJAK
Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAF
Cornea, External Disease & Refractive Surgery (LASIK/PRK)
NAICS code1 code
  • Ophthalmic Goods Manufacturing339115
SIC code1 code
  • Ophthalmic Goods3851
Product category
Ophthalmic Medical Devices
Social media profiles3 records
Cost components5 values
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

AcuFocus develops, manufactures, and markets the KAMRA corneal inlay, an ocular implant used by ophthalmic surgeons to treat presbyopia (near vision loss) in patients seeking surgical vision correction. The company's KAMRA inlay is a small-aperture corneal implant designed to restore near vision while maintaining distance vision, addressing age-related loss of near vision through a refractive surgical procedure.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1KAMRA Inlay
CategoryRefractive Surgery Implants
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Presbia developed the Presbia Flexivue Microlens, a corneal inlay for presbyopia correction, making it a direct competitor in the small-aperture corneal inlay category alongside AcuFocus's KAMRA inlay.

TypeBroad incumbent
Description

Bausch + Lomb's surgical division offers cataract and refractive surgery platforms (Stellaris Elite, VICTUS, enVista IOLs) and is both a strategic investor in AcuFocus and a broad incumbent competing across the ophthalmic surgical value chain.

TypeBroad incumbent
Description

Alcon is a global ophthalmic surgery and vision care leader offering premium IOLs, refractive surgery platforms, and presbyopia-correcting solutions, overlapping with AcuFocus's refractive and presbyopia-correcting focus.

TypeBroad incumbent
Description

J&J Vision offers TECNIS multifocal and extended-depth-of-focus IOLs and the iDesign refractive suite, competing with AcuFocus for presbyopia and refractive surgery patients and surgeon adoption.

5Carl Zeiss Meditec
TypeBroad incumbent
Description

Zeiss Meditec supplies premium IOLs (e.g., AT ELANA, CT SPHERIS) and refractive laser systems targeting the same cataract and refractive surgeons that adopt corneal inlay technologies like KAMRA.

TypeDirect peer
Description

STAAR Surgical markets the Visian ICL (Implantable Collamer Lens) for refractive vision correction, making it a peer in vision-correction implantable devices serving myopic patients as an alternative to corneal-based procedures.

TypeEmerging player
Description

Lensar develops femtosecond laser systems for cataract and refractive surgery, addressing the same surgical ophthalmologist customer base as AcuFocus's KAMRA inlay with adjacent refractive procedure technology.

8ReVision Optics (historical)
TypeOthers
Description

ReVision Optics previously developed the Raindrop Near Vision Inlay, a competing corneal inlay for presbyopia that was ultimately withdrawn from the market, illustrating the category risk AcuFocus faces with KAMRA.

TypeBroad incumbent
Description

AbbVie's Allergan eye care franchise includes Vuity (pilocarpine drops) for presbyopia, a non-implant pharmacological competitor that directly targets AcuFocus's patient population with a less invasive alternative.

TypeEmerging player
Description

Lenz Therapeutics is developing pharmacological presbyopia treatments (e.g., aceclidine-based drops), positioning it as a non-invasive alternative to AcuFocus's corneal inlay approach for presbyopia correction.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AcuFocus

Ophthalmic Medical Devicesacufocus.com

AcuFocus firmographics

Firmographics
Name
AcuFocus
Website
https://acufocus.com
Company type
Private
Founded year
2001
Headcount range
101–250 employees
Ownership category
akta.pro rank

AcuFocus industry classification

Industry
Product category
Ophthalmic Medical Devices
NAICS
Ophthalmic Goods Manufacturing (339115)
SIC
Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAHAJAK
Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAF
Cornea, External Disease & Refractive Surgery (LASIK/PRK)

Keywords

  • Ocular implants
  • Vision correction devices
  • Ophthalmic medical devices
  • Presbyopia treatment
  • Refractive surgery implants

Where AcuFocus is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Markets served

AcuFocus business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

AcuFocus product offering

Product offering

Core offering

AcuFocus develops, manufactures, and markets the KAMRA corneal inlay, an ocular implant used by ophthalmic surgeons to treat presbyopia (near vision loss) in patients seeking surgical vision correction. The company's KAMRA inlay is a small-aperture corneal implant designed to restore near vision while maintaining distance vision, addressing age-related loss of near vision through a refractive surgical procedure.

Differentiator

Problem solved

Functional benefit

Products and services

  • KAMRA Inlay

Companies that use AcuFocus

Customer profile

Segments1 record

Ideal customer profiles1 record

AcuFocus technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AcuFocus partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

AcuFocus competitors and assessment

Company assessment

Direct peers

  • Presbia: Presbia developed the Presbia Flexivue Microlens, a corneal inlay for presbyopia correction, making it a direct competitor in the small-aperture corneal inlay category alongside AcuFocus's KAMRA inlay.
  • STAAR Surgical: STAAR Surgical markets the Visian ICL (Implantable Collamer Lens) for refractive vision correction, making it a peer in vision-correction implantable devices serving myopic patients as an alternative to corneal-based procedures.

Broad incumbents

  • Bausch + Lomb (Bausch Surgical): Bausch + Lomb's surgical division offers cataract and refractive surgery platforms (Stellaris Elite, VICTUS, enVista IOLs) and is both a strategic investor in AcuFocus and a broad incumbent competing across the ophthalmic surgical value chain.
  • Alcon: Alcon is a global ophthalmic surgery and vision care leader offering premium IOLs, refractive surgery platforms, and presbyopia-correcting solutions, overlapping with AcuFocus's refractive and presbyopia-correcting focus.
  • Johnson & Johnson Vision: J&J Vision offers TECNIS multifocal and extended-depth-of-focus IOLs and the iDesign refractive suite, competing with AcuFocus for presbyopia and refractive surgery patients and surgeon adoption.
  • Carl Zeiss Meditec: Zeiss Meditec supplies premium IOLs (e.g., AT ELANA, CT SPHERIS) and refractive laser systems targeting the same cataract and refractive surgeons that adopt corneal inlay technologies like KAMRA.
  • AbbVie (Allergan Aesthetics / Eye Care): AbbVie's Allergan eye care franchise includes Vuity (pilocarpine drops) for presbyopia, a non-implant pharmacological competitor that directly targets AcuFocus's patient population with a less invasive alternative.

Emerging players

  • Lensar: Lensar develops femtosecond laser systems for cataract and refractive surgery, addressing the same surgical ophthalmologist customer base as AcuFocus's KAMRA inlay with adjacent refractive procedure technology.
  • Lenz Therapeutics: Lenz Therapeutics is developing pharmacological presbyopia treatments (e.g., aceclidine-based drops), positioning it as a non-invasive alternative to AcuFocus's corneal inlay approach for presbyopia correction.

Others

  • ReVision Optics (historical): ReVision Optics previously developed the Raindrop Near Vision Inlay, a competing corneal inlay for presbyopia that was ultimately withdrawn from the market, illustrating the category risk AcuFocus faces with KAMRA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

AcuFocus social profiles

Digital presence

AcuFocus financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AcuFocus leadership team

Management profile

Number of profiles

Profiles3 records

AcuFocus funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AcuFocus M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AcuFocus

What does AcuFocus do?

AcuFocus develops, manufactures, and markets the KAMRA corneal inlay, an ocular implant used by ophthalmic surgeons to treat presbyopia (near vision loss) in patients seeking surgical vision correction. The company's KAMRA inlay is a small-aperture corneal implant designed to restore near vision while maintaining distance vision, addressing age-related loss of near vision through a refractive surgical procedure.

When was AcuFocus founded?

AcuFocus was founded in 2001. It employs 101 to 250 people.

Where is AcuFocus based?

AcuFocus is headquartered in Irvine, United States, in the North America region.

Who are AcuFocus's main competitors?

Direct peers on record are Presbia and STAAR Surgical. Broad incumbents are Bausch + Lomb (Bausch Surgical), Alcon, Johnson & Johnson Vision, Carl Zeiss Meditec and AbbVie (Allergan Aesthetics / Eye Care). Emerging players are Lensar and Lenz Therapeutics. ReVision Optics (historical) is listed as an others.

Does AcuFocus have an API?

No public API is recorded for AcuFocus.

What industry is AcuFocus in?

AcuFocus's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAK, Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery), with a secondary code of HLAKAKAF, Cornea, External Disease & Refractive Surgery (LASIK/PRK). Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ophthalmology TimesAcuFocus announces first commercial patients treated with its small aperture lens for cataract surgeryAcuFocus announced the commercial implantation of its IC-8 Apthera intraocular lens by Dr. Vance Thompson, marking the start of a controlled limited commercial release in the United States. The company plans to expand its team and train surgeons ahead of the expected full US launch during the second quarter of 2023. This product is the first extended depth of focus lens indicated for monovision and addresses presbyopia in patients with low corneal astigmatism.Ophthalmology TimesA simple solution for complex corneasOphthalmologist Prof. Sathish Srinivasan advocates for the use of small-aperture intraocular lenses, specifically the IC-8 manufactured by AcuFocus, to treat patients with complex corneas following cataract surgery. The article details how this technology provides a forgiving optical solution for irregular corneas caused by prior laser vision correction, disease, or trauma, offering better visual outcomes than traditional monofocal or complex presbyopia-correcting lenses. This approach addresses a significant subset of cataract patients who are otherwise poorly served by standard advanced-technology implants.Ophthalmology TimesFDA approves the AcuFocus IC-8 small aperture IOL for cataract surgeryThe U.S. Food and Drug Administration has approved AcuFocus Inc.'s IC-8 Apthera IOL for the treatment of cataracts, marking the first approval for this small aperture lens design. Clinical trial data indicated that patients achieved statistically superior intermediate and near vision compared to those receiving standard monofocal lenses, while maintaining equivalent distance vision. AcuFocus plans to begin a limited commercial release of the device in the United States in the fall of 2022.Ophthalmology TimesIrregular corneas stand to benefit from small-aperture IOL designThe IC-8 IOL, designed by AcuFocus, utilizes pinhole optics to improve visual acuity for patients with severe corneal irregularities, achieving better intermediate vision and overall visual perception. In a recent study involving 17 patients, 16 showed improved postoperative corrected distance visual acuity following the implantation of the IC-8 IOL, indicating its effectiveness compared to standard lenses. The lens is currently cleared for use in Europe and Asia, and is undergoing trials in the United States.Ophthalmology TimesHow pinhole camera effect in small-aperture implant corrects presbyopiaThe article discusses the IC-8 intraocular lens (IOL) developed by Acufocus, which utilizes a pinhole camera effect to effectively correct presbyopia when paired with multifocal technology. This IOL expands the patient's depth of focus and improves visual acuity for near, intermediate, and far distances, presenting a significant advancement in cataract surgery options. The IC-8 has shown promising results in a study involving patients with previous refractive procedures, indicating its potential for customized outcomes in visual correction.InsightIC-8 IOL: Small aperture, big resultsBausch + Lomb has acquired the IC-8 intraocular lens (IOL), which utilizes small aperture technology and addresses various unmet needs in cataract surgery, as noted by Australian ophthalmologists. The IOL, which was originally developed by AcuFocus, improves visual acuity for patients with irregular corneas and is gaining recognition for its effectiveness in enhancing spectacle independence. This acquisition strengthens Bausch + Lomb's premium IOL portfolio amid a growing global market for cataract lenses.FierceBiotechBausch + Lomb buys cataract lens maker AcuFocusBausch + Lomb has acquired AcuFocus, the maker of the IC-8 Apthera intraocular lens designed to provide an extended depth of field for cataract patients. This acquisition expands Bausch + Lomb's portfolio in the eye care sector, targeting a significant portion of the global cataract patient population. The financial terms of the deal were not disclosed.LwLatham & Watkins Advises AcuFocus in Acquisition by Bausch + LombAn affiliate of Bausch + Lomb has acquired AcuFocus, Inc., a privately held ophthalmic medical device company, through a merger transaction with AcuFocus's parent company. The transaction terms were not disclosed, and Latham & Watkins LLP represented AcuFocus in the deal with a multi-practice legal team. This represents a strategic expansion of Bausch + Lomb's eye health portfolio through the acquisition of a specialized ophthalmic medical device company.Business Wire BlogBausch + Lomb Acquires AcuFocus, Inc.Bausch + Lomb Corporation has acquired AcuFocus, Inc., a privately held ophthalmic medical device company known for its IC-8 Apthera intraocular lens technology. This acquisition is intended to bolster Bausch + Lomb's surgical portfolio and expand its offerings in the growing premium cataract IOL market. The deal includes strategic advisors such as BofA Securities and legal firms Norton Rose Fulbright and Latham & Watkins.Business Wire BlogBausch + Lomb Acquires AcuFocus, Inc.Bausch + Lomb acquired AcuFocus, a privately held ophthalmic device company, via a merger with its parent. AcuFocus's IC-8 Apthera intraocular lens, approved in July 2022, is the first small aperture EDOF IOL for cataract patients with up to 1.5 diopters of corneal astigmatism. The acquisition aims to bolster Bausch + Lomb's surgical portfolio.